As of November 6, 2026, Dianthus Therapeutics, Inc. /DE/ is a publicly traded company (Nasdaq: DNTH); its largest reported holder is T. Rowe Price, with 7.1% on Schedule 13G of August 7, 2026, then BlackRock (6.4%) (Schedule 13G, August 7, 2026).
Is this your company?
About to sign with, pay or invest in Dianthus Therapeutics, Inc. /DE/? See the free Snapshot first.
Free to see. No signup.
Is Dianthus Therapeutics, Inc. /DE/ a real, registered company?
- Dianthus Therapeutics Inc files with the SEC under CIK 1690585 (its SEC filings).
- Its shares are listed under the ticker DNTH on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in New York, New York, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Dianthus Therapeutics Inc in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Vanguard (filed 2026-10-30).
Who are Dianthus Therapeutics, Inc. /DE/'s owners and officers?
Dianthus Therapeutics, Inc. /DE/: incorporated in Delaware; business address in New York, New York; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-30).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-30 | Vanguard Capital Management | 5.08% |
| Schedule 13G/A, 2026-08-14 | Sirenia Capital Management LP | 3.1% |
| Schedule 13G, 2026-08-13 | Wellington Management Group LLP | 5.9% |
| Schedule 13G, 2026-08-07 | T. Rowe Price Investment Management, Inc. | 7.1% |
| Schedule 13G/A, 2026-08-07 | T. Rowe Price Investment Management, Inc. | 12.1% |
| Schedule 13G/A, 2026-07-28 | Blackrock, Inc. | 6.4% |
| Schedule 13G, 2026-05-15 | Sirenia Capital Management LP | 5.3% |
| Schedule 13G/A, 2026-05-15 | Ra Capital Management, L.P. | 4.8% |
| Schedule 13G/A, 2026-05-15 | Point72 Asset Management, L.P. | 1.2% |
| Schedule 13G/A, 2026-05-15 | Wellington Management Group LLP | 4.8% |
| Schedule 13G/A, 2026-05-14 | Octagon Capital Advisors LP | 3.6% |
| Schedule 13G, 2026-04-27 | Blackrock, Inc. | 5.1% |
Questions about who owns Dianthus Therapeutics, Inc. /DE/
Who owns Dianthus Therapeutics, Inc. /DE/?
On this page, 4 holders' latest ownership filings report 5% or more of Dianthus Therapeutics, Inc. /DE/: T. Rowe Price Investment Management, Inc. (7.1%, Schedule 13G, filed 2026-08-07), Blackrock, Inc. (6.4%, Schedule 13G/A, filed 2026-07-28), Wellington Management Group LLP (5.9%, Schedule 13G, filed 2026-08-13) and Vanguard Capital Management (5.08%, Schedule 13G, filed 2026-10-30).
Who are the largest shareholders of Dianthus Therapeutics, Inc. /DE/?
By the share each holder's latest filing reports, the largest holders of Dianthus Therapeutics, Inc. /DE/ on this page are T. Rowe Price Investment Management, Inc. (7.1%), Blackrock, Inc. (6.4%) and Wellington Management Group LLP (5.9%).
When did T. Rowe Price Investment Management, Inc. buy into Dianthus Therapeutics, Inc. /DE/?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Investment Management, Inc. on this page is the Schedule 13G, filed 2026-08-07, reporting 7.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Dianthus Therapeutics, Inc. /DE/?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Dianthus Therapeutics, Inc. /DE/: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dianthus Therapeutics, Inc. /DE/ covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Dianthus Therapeutics, Inc. /DE/ shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 2,700,691 shares (4.8% of shares outstanding), held indirectly through By Fairmount SPV III, LLC and 1 other, on a joint filing (Form 4, 2024-10-01).
- Fairmount Funds Management LLC, a director: 2,700,691 shares (4.8% of shares outstanding), held indirectly through By Fairmount SPV III, LLC and 1 other, on a joint filing (Form 4, 2024-10-01).
- , the chief executive and president: 65,292 shares (0.12% of shares outstanding) (Form 4, 2026-08-07).
- , the general counsel and senior vice president: 15,000 shares (0.03% of shares outstanding) (Form 4, 2026-08-14).
- , the executive vice president and head of r: 4,000 shares (0.01% of shares outstanding) (Form 4, 2026-09-03).
Shares outstanding: 56,312,712 as of 2026-11-02, from the company's latest SEC cover page.
How much has Dianthus Therapeutics, Inc. /DE/ raised?
Latest IPO step: Dianthus Therapeutics, Inc. /DE/ withdrew its IPO registration (RW, 2024-10-21).
IPO filings: RW, 2024-10-21.
Keep reading
More on Dianthus Therapeutics, Inc. /DE/ and the records around it.
Dianthus Therapeutics, Inc. /DE/ elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- BCLS Fund III Investments, LP also filed stake reports on 3 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Heartflow, Inc. (Aug 2026), CIDARA THERAPEUTICS, INC. (Feb 2026)
- Avidity Partners Management LP also filed stake reports on 5 other companies: Context Therapeutics Inc. (May 2026), Immunic, Inc. (Apr 2026), Perspective Therapeutics, Inc. (Mar 2026)
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Precision BioSciences, Inc. (Nov 2026), Context Therapeutics Inc. (Jul 2026), Corbus Pharmaceuticals Holdings, Inc. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/dianthus-therapeutics